Pulmocide  a clinical-stage company today announces the successful dosing of PC786 in a phase 1 study.
PC786 is a potent inhibitor of RSV L polymerase which is delivered by inhaled administration for
the treatment of RSV A and B strains.

PC786 is a novel compound which has been designed to be administered via inhalation to the lungs
which results in high local concentrations at the site of viral replication in the airways.
Delivered at low doses, PC786 has limited systemic exposure which is expected to offer an excellent
safety profile.